We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Quest Diagnostics to Buy Shiel to Widen Footprint in NY-NJ
Read MoreHide Full Article
On an inorganic expansion spree, Quest Diagnostics Incorporated (DGX - Free Report) has recently entered into yet another acquisition agreement. The company has decided to purchase Fresenius Medical Care’s medical laboratory business, Shiel.
Although financial terms of the deal have been kept under wraps, Quest Diagnostics expects the deal to close in the fourth quarter of 2017, subject to customary regulatory approvals.
Notably, Shiel is a clinical laboratory provider of Fresenius Medical Care, a premier healthcare company particularly working on renal and other chronic conditions in patients. The lab specifically serves in the New York-New Jersey metropolitan area.
Per Quest Diagnostics, post completion of the buyout, Shiel will provide broader access to the company’s diagnostic insights and innovations for physicians and patients in the New York-New Jersey region. The takeover is expected to expand Quest Diagnostics’ patient service centers network in the region.
Additionally, care providers will have direct access to Quest Diagnostics’ broader menu of services. The ones currently provided by Shiel’s laboratories in Rockleigh, NJ and Brooklyn, NY, will now shift to the company’s flagship clinical laboratory in Teterboro, NJ.
Quest Diagnostics and Fresenius Medical Care will jointly work on identifying patients with early-stage chronic kidney disease, with potential to benefit from treatment to slow progression to end-stage renal disease (ESRD), based on the former’s laboratory data analytics.
Quest Diagnostics’ merger and acquisition activity is believed to be a key growth driver, functioning in full swing. Notably, the company has been of late focusing on tactics to accelerate growth and drive operational excellence through strategically aligned, accretive acquisitions. Worth reckoning is the company’s recent consolidation with an outreach operation of PeaceHealth Laboratories.
Per the company, these tuck-in acquisitions fit well within the ambit of M&A guidelines. Quest Diagnostics’ takeover plans are consistent with its goal of contributing 1-2% revenue growth annually through accretive acquisitions.
Year to date, the company has outperformed the broader industry. Per the last share price movement, the stock has gained 1.9% in contrast to the broader industry’s 3.9% decline during the period.
Zacks Rank & Key Picks
Quest Diagnostics carries a Zacks Rank #3 (Hold). A few better-ranked stocks in the medical sector are Orthofix International N.V. (OFIX - Free Report) , Owens & Minor, Inc. (OMI - Free Report) and OraSure Technologies, Inc. (OSUR - Free Report) . While both Orthofix International and Owens & Minorsport a Zacks Rank #1 (Strong Buy), OraSure Technologies carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Orthofix International has a long-term expected earnings growth rate of 11.8%. The stock has gained roughly 3% over the last three months.
Owens & Minorhas a long-term expected earnings growth rate of 5%. The stock has gained 4.4% over the last month.
OraSure Technologies has a long-term expected earnings growth rate of 16%. The stock has gained 9.1% over the last month.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Quest Diagnostics to Buy Shiel to Widen Footprint in NY-NJ
On an inorganic expansion spree, Quest Diagnostics Incorporated (DGX - Free Report) has recently entered into yet another acquisition agreement. The company has decided to purchase Fresenius Medical Care’s medical laboratory business, Shiel.
Although financial terms of the deal have been kept under wraps, Quest Diagnostics expects the deal to close in the fourth quarter of 2017, subject to customary regulatory approvals.
Notably, Shiel is a clinical laboratory provider of Fresenius Medical Care, a premier healthcare company particularly working on renal and other chronic conditions in patients. The lab specifically serves in the New York-New Jersey metropolitan area.
Per Quest Diagnostics, post completion of the buyout, Shiel will provide broader access to the company’s diagnostic insights and innovations for physicians and patients in the New York-New Jersey region. The takeover is expected to expand Quest Diagnostics’ patient service centers network in the region.
Additionally, care providers will have direct access to Quest Diagnostics’ broader menu of services. The ones currently provided by Shiel’s laboratories in Rockleigh, NJ and Brooklyn, NY, will now shift to the company’s flagship clinical laboratory in Teterboro, NJ.
Quest Diagnostics and Fresenius Medical Care will jointly work on identifying patients with early-stage chronic kidney disease, with potential to benefit from treatment to slow progression to end-stage renal disease (ESRD), based on the former’s laboratory data analytics.
Quest Diagnostics’ merger and acquisition activity is believed to be a key growth driver, functioning in full swing. Notably, the company has been of late focusing on tactics to accelerate growth and drive operational excellence through strategically aligned, accretive acquisitions. Worth reckoning is the company’s recent consolidation with an outreach operation of PeaceHealth Laboratories.
Per the company, these tuck-in acquisitions fit well within the ambit of M&A guidelines. Quest Diagnostics’ takeover plans are consistent with its goal of contributing 1-2% revenue growth annually through accretive acquisitions.
Quest Diagnostics Incorporated Price
Quest Diagnostics Incorporated Price | Quest Diagnostics Incorporated Quote
Year to date, the company has outperformed the broader industry. Per the last share price movement, the stock has gained 1.9% in contrast to the broader industry’s 3.9% decline during the period.
Zacks Rank & Key Picks
Quest Diagnostics carries a Zacks Rank #3 (Hold). A few better-ranked stocks in the medical sector are Orthofix International N.V. (OFIX - Free Report) , Owens & Minor, Inc. (OMI - Free Report) and OraSure Technologies, Inc. (OSUR - Free Report) . While both Orthofix International and Owens & Minorsport a Zacks Rank #1 (Strong Buy), OraSure Technologies carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Orthofix International has a long-term expected earnings growth rate of 11.8%. The stock has gained roughly 3% over the last three months.
Owens & Minorhas a long-term expected earnings growth rate of 5%. The stock has gained 4.4% over the last month.
OraSure Technologies has a long-term expected earnings growth rate of 16%. The stock has gained 9.1% over the last month.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>